GLUT-1 Expression in Breast Cancer
OBJECTIVE: Numerous studies have been conducted to predict the prognosis of breast cancers. The effect of glucose transporter protein 1 (GLUT-1), the main carrier protein responsible for glucose transport, was investigated in breast cancer patients.
MATERIAL AND METHOD: 170 patients operated for breast carcinoma were included in this study. We analysed the prognostic significance of GLUT-1 immune-expression in 149 patients without neoadjuvant therapy, and in 21 patients with neoadjuvant therapy.
RESULTS: GLUT-1 expression was correlated with poor prognostic factors such as estrogen receptor and progesterone receptor negativity, high Ki-67 proliferation index, and high histological and nuclear grade (p < 0.001). GLUT-1 was expressed at a statistically higher rate in invasive ductal carcinomas, compared to invasive lobular carcinomas (p < 0.001), and was expressed at a higher rate in luminal B, human epidermal growth factor receptor 2 and triple-negative molecular subtypes compared to luminal A subtype tumors (p < 0.001). There was no statistically significant difference between GLUT-1 expression and presence of neoadjuvant therapy. Univariate survival analysis showed high GLUT1 expression was associated with low disease-free survival.
CONCLUSION: GLUT-1 expression was found to be associated with poor pathological prognostic factors in breast carcinoma patients. The results suggest that GLUT-1 expression can be considered as a prognostic marker in breast cancers, and it may be used as a target molecule in personalized treatment approaches.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:38 |
|---|---|
| Enthalten in: |
Turk patoloji dergisi - 38(2022), 2 vom: 27., Seite 114-121 |
| Sprache: |
Englisch |
|---|
| Weiterer Titel: |
GLUT-1 Expression in Breast Cancer |
|---|
| Beteiligte Personen: |
Okcu, Oguzhan [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Biomarkers, Tumor |
|---|
| Anmerkungen: |
Date Completed 18.05.2022 Date Revised 22.04.2023 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.5146/tjpath.2021.01557 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM331224372 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM331224372 | ||
| 003 | DE-627 | ||
| 005 | 20231225213007.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.5146/tjpath.2021.01557 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1104.xml |
| 035 | |a (DE-627)NLM331224372 | ||
| 035 | |a (NLM)34580846 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Okcu, Oguzhan |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a GLUT-1 Expression in Breast Cancer |
| 246 | 3 | 3 | |a GLUT-1 Expression in Breast Cancer |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 18.05.2022 | ||
| 500 | |a Date Revised 22.04.2023 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a OBJECTIVE: Numerous studies have been conducted to predict the prognosis of breast cancers. The effect of glucose transporter protein 1 (GLUT-1), the main carrier protein responsible for glucose transport, was investigated in breast cancer patients | ||
| 520 | |a MATERIAL AND METHOD: 170 patients operated for breast carcinoma were included in this study. We analysed the prognostic significance of GLUT-1 immune-expression in 149 patients without neoadjuvant therapy, and in 21 patients with neoadjuvant therapy | ||
| 520 | |a RESULTS: GLUT-1 expression was correlated with poor prognostic factors such as estrogen receptor and progesterone receptor negativity, high Ki-67 proliferation index, and high histological and nuclear grade (p < 0.001). GLUT-1 was expressed at a statistically higher rate in invasive ductal carcinomas, compared to invasive lobular carcinomas (p < 0.001), and was expressed at a higher rate in luminal B, human epidermal growth factor receptor 2 and triple-negative molecular subtypes compared to luminal A subtype tumors (p < 0.001). There was no statistically significant difference between GLUT-1 expression and presence of neoadjuvant therapy. Univariate survival analysis showed high GLUT1 expression was associated with low disease-free survival | ||
| 520 | |a CONCLUSION: GLUT-1 expression was found to be associated with poor pathological prognostic factors in breast carcinoma patients. The results suggest that GLUT-1 expression can be considered as a prognostic marker in breast cancers, and it may be used as a target molecule in personalized treatment approaches | ||
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a Biomarkers, Tumor |2 NLM | |
| 650 | 7 | |a Glucose Transporter Type 1 |2 NLM | |
| 650 | 7 | |a Ki-67 Antigen |2 NLM | |
| 650 | 7 | |a Receptors, Progesterone |2 NLM | |
| 650 | 7 | |a SLC2A1 protein, human |2 NLM | |
| 650 | 7 | |a Receptor, ErbB-2 |2 NLM | |
| 650 | 7 | |a EC 2.7.10.1 |2 NLM | |
| 700 | 1 | |a Sen, Bayram |e verfasserin |4 aut | |
| 700 | 1 | |a Ozturk, Cigdem |e verfasserin |4 aut | |
| 700 | 1 | |a Guvendi, Gulname Findik |e verfasserin |4 aut | |
| 700 | 1 | |a Bedir, Recep |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Turk patoloji dergisi |d 1998 |g 38(2022), 2 vom: 27., Seite 114-121 |w (DE-627)NLM093836945 |x 1309-5730 |7 nnns |
| 773 | 1 | 8 | |g volume:38 |g year:2022 |g number:2 |g day:27 |g pages:114-121 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.5146/tjpath.2021.01557 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 38 |j 2022 |e 2 |b 27 |h 114-121 | ||